Gaucher disease is a rare autosomal recessive disorder of glycosphingolipid metabolism resulting from deficient activity of the lysosomal enzyme beta-glucocerebrosidase that causes accumulation of glucosylceramide in tissue macrophage with damage to hematological, visceral, and skeletal organ systems. Severity and progression may vary independently among these domains, necessitating individualized therapy. Skeletal involvement is highly prevalent and often associated with intense pain, impaired mobility, and reduced quality of life. Enzyme replacement therapy improves parameters in all affected domains, but skeletal involvement requires longer treatment and higher dosages to obtain significant results. Despite numerous papers on bone complications in patients with Gaucher disease, there are no specific indications on how to assess properly bone involvement in such condition, the frequency
INTRODUCTION
Gaucher disease (GD; OMIM #230800) is a rare autosomal recessive hereditary disorder of glycosphingolipid metabolism resulting from deficient activity of the lysosomal enzyme b-glucocerebrosidase (EC 3.2.1.45; lysosomal glucocerebrosidase). Glucosylceramide accumulates in macrophages (Gaucher cells) in the spleen, liver, and bone marrow. Although GD has a continuous spectrum of severity, it is traditionally classified into three forms: type 1 (chronic; lacking early onset neuronopathy), type 2 (acute; with early onset neuronopathy), and type 3 (chronic; with early onset neuronopathy) [1] . Type 1 GD accounts for the vast majority of cases, with an incidence of approximately 1/40-60,000 in the general population [2, 3] and 1/500 in the Ashkenazy population [4] .
GD type 1 is a chronic multi-organ disorder with a variety of signs and symptoms that include hepatomegaly, splenomegaly, (pan)cytopenia, pulmonary disease, and various bone manifestations. The severity and clinical course of the disease are extremely heterogeneous, varying between patients and affected domains in the same patient [1] . Bone pathology in GD affects both the marrow and structural compartments, although the precise pathophysiological mechanisms are not yet well understood. Bone marrow infiltration by Gaucher cells may cause vascular occlusion, ischemia, and compression, whereas mineralization defects may result from abnormal bone remodeling [1] . Skeletal manifestations are the most disabling long-term complication of GD, and more than 80% of patients have signs of bone involvement at diagnosis [5, 6] . These may include abnormal bone remodeling, osteopenia, lytic lesions, pathological fractures, vertebral collapse, and avascular osteonecrosisparticularly at the femoral or humeral headswith possible bone collapse and joint involvement [7] . Osteopenia is common in patients with GD, and often occurs early in life, resulting in reduced bone mineral density (BMD) with lower peak bone mass and increased risk of complications associated with bone fragility [8] .
Skeletal involvement is a compelling indication for enzyme replacement therapy (ERT) and some bone parameters are key treatment goals [8, 9] . While patients with bone pain and bone crisis resulting from bone marrow infiltration generally respond to ERT within 2 years [10] , improvement of bone mineral density (BMD) is markedly dosedependent and requires up to 8 years of highdosage therapy to normalize [11] . Some bone manifestations are irreversible [12] ; thus, early and sustained treatment is critical. Adequate treatment is especially important during adolescence and early adulthood, when peak bone mass is accrued [13] . Moreover, early treatment may reduce the risk of avascular bone necrosis [14] . Over time, impaired quality of life (QoL) may become refractory to therapy due to the occurrence of permanent bone sequelae and the need for joint replacements [15, 16] .
Guidelines have been elaborated for the diagnosis, treatment and follow-up of patients with GD [17, 18] ; however, detailed information on the correct evaluation and interpretation of skeletal involvement are lacking. The aim of this paper was to propose a methodological and critical approach to the diagnosis, follow-up, and treatment of bone disease in patients with GD type 1.
METHODS
To address the unmet need for improving the approach to bone disease in GD, 
DISCUSSION

Imaging Methods for Assessing Bone Damage
Dual Energy X-ray Absorptiometry (Table 1) The gold standard for quantitative assessment of bone mineral status in adults is dual energy X-ray absorptiometry (DXA), performed at the lumbar spine (L1-L4) and hip (total hip or femoral neck). In children, in addition to DXA performed on the L1-L4 lumbar vertebrae, scans of the total body less head (TBLH) are mandatory, whereas measurement of BMD at the femur is not recommended due to high variability in skeletal maturity [19] . How to Perform DXA Measurement of BMD at the lumbar spine should be performed in the anteroposterior projection, considering the mean BMD of at least two vertebrae among L1-L4, excluding any vertebrae with defects or artifacts. The femoral neck or total hip is the optimal site for fracture risk assessment [22] . In certain circumstances (e.g., for very obese patients or the presence of bone damage in Regarding methodological variability and the accuracy of measurements, the precision error and least significant change (LSC) detectable must be determined for each DXA apparatus, independently from the information provided by the manufacturer. Strict adherence to protocols is required to obtain accurate results. by comparison to other methods, and interrater reliability has been assessed at multiple centers [24] [25] [26] [27] [28] [29] . Of these, the bone marrow burden (BMB) seems to be the most commonly used method.
A quantitative MRI method known as quantitative chemical shift imaging (QCSI) has also been developed [30] . QCSI quantifies fat content using differences in the resonant frequencies of fat and water in bone marrow.
However, it is not universally available, relies on specialist technical input, is time consuming, and prone to both measurement errors and artifacts.
For all these reasons, it is not used in clinical practice. BMI can be measured using scintigraphic imaging with semi-quantitative assessment; however, whereas it is widely available, this method has low specificity, and physiological excretion of markers hampers assessment of the abdominal region. Recently, Di Rocco et al. [3] have normalized these methods so that their results are now comparable, allowing clinicians and radiologists to use any one of these methods ( Table 3) .
Frequency of MRI Follow-Up The International
Registry Collaborative Gaucher Group (ICGG) has developed recommendations for effective monitoring of adult patients with GD type 1 [17] . These indicate that MRI should be performed at diagnosis and then every 12-24 months for patients not receiving ERT and for those who have not achieved therapeutic goals while receiving ERT, whereas patients who have achieved therapeutic goals while receiving ERT should be monitored every 24-36 months.
Assessments should be performed also when changing therapy or in the event of significant clinical complications. Therapeutic goals for BMI have not been established.
Follow-up imaging may be less frequent in untreated patients with minimal disease who lack evidence of progression over several years, or in treated patients with negligible BMI and evidence of stable disease. Conversely, evaluations should be more frequent in untreated symptomatic patients with significant disease burden [17] .
MRI is cost-effective in terms of diagnostic value and the cost of therapy; however, it is expensive and for this reason, we propose the following protocol. At baseline, total body semiquantitative MRI should be used to check for osteonecrosis in sites other than the femoral head [31] . The same semi-quantitative method should be used for follow-up. However, in our opinion, total body MRI is not useful for followup. Instead, we suggest performing MRI on specific symptomatic regions.
If the baseline normalized score (see Table 2 )
is B1, MRI should be performed every 24 months; if it is [1, MRI should be performed every 12 months. In stable patients with good metabolic control and scores 
Plain Radiography
Radiographic examination is widely available and inexpensive, but it has low sensitivity in detecting initial and small changes in skeletal involvement in GD patients [7] . However, it is useful for detecting bone complications such as fractures. In addition, radiographic imaging may reveal skeletal lesions, cortical bone thinning, and Erlenmeyer flask deformation that may lead to incidental diagnosis of GD in asymptomatic patients.
The guideline developed by the International Collaborative Gaucher Group (ICGG) recommends that the initial assessment include X-ray examination of the femora, spine, and any other symptomatic sites, but indicates that MRI provides much more information on BMB [17] . Conventional radiography may be useful for characterizing osteonecrosis of the proximal femur and osteosclerotic areas, when used in the context of an appropriate classification system. Steinberg has proposed a classification system that we agreed is useful for identifying progression of radiographic damage and providing information to guide surgical approaches (Steinberg et al. 1998) . It is derived from the system of Arlet and Ficat [32] and includes additional stages (Table 4) .
Biomarkers for Bone Damage
Bone manifestations commonly involve decreases or increases in the rate of bone turnover and imbalance between bone resorption and formation. Bone turnover can
be measured with specific biochemical markers [60] for enzyme activities, the release of various structural components of bone, and proteins involved in the processes of bone formation (Table 5) . Over the years, most of these parameters have been tested in patients with GD [33] [34] [35] [36] [37] [38] [39] [40] . Urinary total hydroxyproline levels are used to identify osteoclastic hyperactivity.
Stowens et al. [41] reported a reduction in urinary hydroxyproline levels in about one-third of patients with GD compared with controls, suggesting a reduction in bone resorption in these patients. Furthermore, osteoblast activity also appears to be suppressed in patients with GD not treated with replacement therapy, as demonstrated by a threefold decrease in levels of markers of osteoblast activity: osteocalcin [34] and carboxy-terminal propeptide of procollagen type 1 (P1NP) [35] . More recently, Van Dussen et al [40] . reported a significant reduction in osteocalcin levels, without significant changes in levels of carboxy-terminal telopeptide of type I collagen (CTX, a marker of osteoclast activity), in 50% of patients with GD type 1, suggesting that the altered bone turnover is mainly characterized by a reduction of bone formation. Moreover, Mikosch et al. [38] 
Enzyme Replacement Therapy
The availability of enzyme replacement therapy (ERT) has significantly improved the treatment of GD, making it possible to establish meaningful therapeutic goals for skeletal manifestations of GD (Table 6 ). Three recombinant mannoseterminated forms of glucocerebrosidase are available for ERT: imiglucerase [43] was approved in 1994, velaglucerase alfa [44] was approved in the US and Europe in 2010, and taliglucerase alfa [45] was approved in the US and Tables 1 and 2 ) and thus may prevent serious skeletal complications such as bone collapse and fractures. Moreover, post-marketing pharmacosurveliance of more than 4,500 patients reveals that imiglucerase is associated with a stable and low rate of adverse events [46] . ERT improves the visceral aspects of GD in the first year, whereas skeletal involvement requires a longer treatment period [10] .
Improvements in bone marrow infiltration are seen within the first 3 years of treatment with ERT [25] , and better results are achieved at higher dosages [47] . A meta-analysis of clinical studies evaluated the effects of ERT on bone complications from GD, suggesting that the bone marrow fat fraction increases significantly following treatment and that 70% of adults with GD respond to treatment [48] . ERT increases the hyperintense T1-weighted MRI signal in bone marrow and significantly reduces BMB scores in patients with GD [28, 49] . On the other hand, normalization of BMD requires long-term treatment for up to 8 years, and there is a clear dose-response relationship [11, 50] . Appropriate dosage is based on disease severity and the risk of progression. Patients are considered to have high-risk disease if they have symptomatic skeletal involvement, significant visceral or hematological involvement, or, in the case of pediatric patients, if they exhibit growth failure [51] . The patient in Case 2 (Supplement) had a low BMD for his age (T-score -3.16) and had experienced a vertebral collapse. BMD did not respond to initial low-dose imiglucerase therapy; however, increasing the dosage to 60 U/kg every 2 weeks was associated with gradual normalization of BMD.
Data on 889 patients in the International Collaborative Gaucher Group (ICGG) registry revealed low BMD for chronological age among patients in all age groups, with the highest prevalence among adolescents [8] . ERT improved bone mass in all age groups, but the greatest effect was seen in younger subjects, emphasizing that a therapeutic window of opportunity exists and that high-dosage therapy may have the greatest effect in younger patients during the period when peak bone mineral density is accrued. Starting ERT sooner after diagnosis of GD is associated with better outcomes for avascular necrosis [14] and for bone outcomes in general [8] . However, ERT is also effective at stabilizing or slowing the progression of bone disease in adult patients who are diagnosed or treated late and may not have achieved peak bone density.
In patients with suboptimal bone responses to ERT, differential diagnosis should exclude other diseases that can mimic osteoporosis (e.g., osteomalacia, myelomatosis). It is very important to continue ERT at an optimal dosage in patients with poor or partial bone responses while evaluating concomitant conditions that may be driving bone mineral loss, such as hyperthyroidism, Cushing syndrome, hypogonadism, alcoholism, glucocorticoid therapy, or vitamin D deficiency. 
CONCLUSION
The severity of skeletal involvement in type 1 GD is variable, but associated with significant pain, disability, and reduced QoL; thus, all patients should be monitored regularly for the onset and progression of skeletal pathology. Looking to the future, therapies combining ERT with SRT have the potential to provide further benefits [58] ; however, a small 24-month controlled study did not show a significant benefit for combination therapy with imiglucerase plus miglustat, compared to either drug in monotherapy [59] 
